# US 6,727,283 B2 · Sertraline oral concentrate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,283 B2
- Document ID: US6727283B2
- Status: Granted
- Kind: B2
- Application number: 09/417,175
- Filed: 1999-10-11
- Published: 2003-05-22
- Granted: 2004-04-27
- Earliest claimed: 1998-10-13
- Assignees: Pfizer Inc.
- Inventors: Nancy J. Harper; Gautam R. Ranade; Willard M. Welch
- Web page: https://patentgrep.com/patent/US6727283B2

## CPC

- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.

## Claims

### Claim 1

A pharmaceutical composition which comprises;
an essentially nonaqueous, filterable, liquid concentrate solution of sertraline hydrochloride for oral administration comprising about 18 mg/ml to about 78 mg/ml of sertraline hydrochloride and ethanol and glycerin in an amount of about 8 to about 50% ethanol by weight in glycerin.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the concentrate further comprises one or more flavoring agents and one or more pharmaceutically acceptable preservatives.

### Claim 3 (depends on 2)

The composition of claim 2 wherein the flavoring agents are selected from the group consisting of peppermint, spearmint and menthol; and wherein the preservatives are selected from the group consisting of butylhydroxytoluene, butylated hydroxyanisole, propyl gallate, ascorbic acid, ascorbyl palmitate, sodium metabisulfite, sodium bisulfite, sodium thiosulfate, sodium hydroxide, cysteine, ethylenediamine tetraacetic acid or salts thereof, citric acid, triethanolamine, thioglycerol, methylparaben and propylparaben.

### Claim 4 (depends on 3)

The composition of claim 3 wherein the flavoring agent is menthol and wherein the preservative is butylhydroxytoluene.

### Claim 5 (depends on 4)

The composition of claim 4 wherein each ml of the concentrate comprises about 22.4 mg of sertraline hydrochloride, about 151 mg of ethanol, about 0.50 mg of menthol, about 0.10 mg of butylhydroxytoluene, and about 1011 mg of glycerin.

### Claim 6 (depends on 1)

A method of using an essentially nonaqueous, liquid concentrate of sertraline hydrochloride of claim 1 to prepare an aqueous solution of sertraline which comprises diluting the concentrate in an aqueous diluent prior to oral administration.

### Claim 7 (depends on 6)

The method of claim 6 wherein the diluent is selected from the group consisting of water, orange juice, ginger ale, lemon-lime soda and lemonade.

### Claim 8 (depends on 1)

A method of treating or preventing diseases or conditions which are caused by disorders of the serotonergic system which comprises:
a) diluting an essentially nonaqueous, liquid concentrate of sertraline hydrochloride of claim 1 in an aqueous diluent; and
b) orally administering the resulting aqueous solution to a patient in need thereof.

### Claim 9 (depends on 8)

The method of claim 8 wherein the diluent is selected from the group consisting of: water, orange juice, ginger ale, lemon-lime soda and lemonade.

### Claim 10 (depends on 1)

A method of treating or preventing diseases or conditions selected from the group consisting of depression, anorexia, chemical dependencies, anxiety-related disorders, premature ejaculation and post myocardial infarction, which comprises:
a) diluting an essentially nonaqueous, liquid concentrate of sertraline hydrochloride of claim 1 in an aqueous diluent; and
b) orally administering the resulting aqueous solution to a patient in need thereof.

### Claim 11 (depends on 10)

The method of claim 10 wherein the anxiety-related disorders are selected from the group consisting of: panic disorder, obsessive-compulsive disorder, generalized anxiety disorder, phobias, post traumatic stress disorder and avoidant personality disorder.

### Claim 12 (depends on 10)

The method of claim 10 wherein the diluent is selected from the group consisting of: water, orange juice, ginger ale, lemon-lime soda and lemonade.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1 comprising about 18 mg/ml to about 30 mg/ml of sertraline hydrochloride and ethanol and glycerin in an amount of about 8 to about 20% ethanol by weight in glycerin.
